These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9444808)

  • 41. MGMA joins Marshfield's appeal.
    Jaklevic MC
    Mod Healthc; 1995 Aug; 25(32):32. PubMed ID: 10144478
    [No Abstract]   [Full Text] [Related]  

  • 42. The sleeping giant awakens: the physician and the antitrust laws.
    Hirsh HL
    Leg Med; 1985; ():334-56. PubMed ID: 3835424
    [No Abstract]   [Full Text] [Related]  

  • 43. Antitrust assault on hospital-Blue Cross relations.
    Davis CD
    Tex Hosp; 1984 Feb; 39(9):46-7. PubMed ID: 10278223
    [No Abstract]   [Full Text] [Related]  

  • 44. An analysis of recent antitrust issues affecting specialty practice: is dermatology immune?
    Gibofsky A
    Semin Cutan Med Surg; 2005 Sep; 24(3):137-43. PubMed ID: 16202949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Minimizing antitrust risks of Blue Cross and Blue Shield plans.
    Steele CJ
    J Contemp Health Law Policy; 1988; 4():227-72. PubMed ID: 10288422
    [No Abstract]   [Full Text] [Related]  

  • 46. A competitive analysis of most favored nations clauses in contracts between health care providers and insurers.
    Celnicker A
    Spec Law Dig Health Care (Mon); 1991 Dec; (154):7-36. PubMed ID: 10115476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The fraud and abuse statute in an evolving health care marketplace: life in the health care speakeasy.
    Blumstein JF
    Am J Law Med; 1996; 22(2-3):205-31. PubMed ID: 8862242
    [No Abstract]   [Full Text] [Related]  

  • 48. Assembled Products: The Key to More Effective Competition And Antitrust Oversight in Health Care.
    Sage WM
    Cornell Law Rev; 2016; 101(3):609-700. PubMed ID: 27062731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analysis of physician antitrust exemption legislation: adjusting the balance of power.
    Hellinger FJ; Young GJ
    JAMA; 2001 Jul; 286(1):83-8. PubMed ID: 11434831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitrust law in 1995: mixed messages for providers.
    Enders RJ
    Health Syst Rev; 1996; 29(2):39-40, 44, 46-7. PubMed ID: 10156518
    [No Abstract]   [Full Text] [Related]  

  • 51. Alternatives for clinical integration: antitrust law considerations.
    Buchanan RM
    Int Ophthalmol Clin; 1998; 38(3):27-44. PubMed ID: 9742431
    [No Abstract]   [Full Text] [Related]  

  • 52. The Settlement of the Blue Cross Blue Shield Antitrust Litigation: Creating a New Potential Catalyst for Health Insurance Industry Restructuring.
    Brennan T
    JAMA Health Forum; 2022 Dec; 3(12):e224737. PubMed ID: 36525255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vertical restraints and powerful health insurers: exclusionary conduct masquerading as managed care?
    Miller FH
    Law Contemp Probl; 1988; 51(2):195-236. PubMed ID: 10295963
    [No Abstract]   [Full Text] [Related]  

  • 54. Antitrust, competition, and health care reform.
    Bloch RE; Falk DM
    Health Aff (Millwood); 1994; 13(1):206-23. PubMed ID: 8188136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vertical restraints among hospitals, physicians and health insurers that raise rivals' costs. A case study of Reazin v. Blue Cross and Blue Shield of Kansas, Inc. and Ocean State Physicians Health Plan, Inc. v. Blue Cross and Blue Shield of Rhode Island.
    Baker JB
    Am J Law Med; 1988; 14(2-3):147-69. PubMed ID: 3245541
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Health insurance purchasing alliances: monopsony threat or procompetitive Rx for health sector ills?
    Miller FH
    Cornell Law Rev; 1994 Sep; 79(6):1546-72. PubMed ID: 10141443
    [No Abstract]   [Full Text] [Related]  

  • 57. Managed competition, antitrust, and the Clinton health reform plan: too modest a proposal.
    Kopit WG
    Healthspan; 1993 Nov; 10(10):21-4. PubMed ID: 10130836
    [No Abstract]   [Full Text] [Related]  

  • 58. Antitrust implications of alternative delivery systems.
    Steren EJ; Stewart BR
    Clin Lab Manage Rev; 1996; 10(5):561-7. PubMed ID: 10162021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managed care competition and the antitrust laws. U.S. Healthcare, Inc. v. Healthsource, Inc.
    Enders RJ
    Health Care Law Newsl; 1993 Aug; 8(8):12-5. PubMed ID: 10183916
    [No Abstract]   [Full Text] [Related]  

  • 60. Legal obstacles to medical communities' full participation in managed care.
    Hilgers DW
    J Health Care Finance; 1995; 21(3):9-16. PubMed ID: 7600242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.